Accomplished Scientific Leader and GSK Veteran, Dean Edney Joins Sai Life Sciences

PR82942

HYDERABAD, India, Feb. 19, 2020 /PRNewswire=KYODO JBN/ --

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing

Organizations (CDMOs) [https://www.sailife.com/?utm_source=dean-edney-pr ],

today announced the appointment of Dr. Dean Edney as Senior Vice President and

Global Head of Process Research & Development. An accomplished scientific leader

and industry veteran with over 25 years of experience in small molecule pharmaceutical

process and product development, Dean Edney will split his time between the company’s

R&D centre in Hyderabad, India and the new R&D facility in Alderley Park, Manchester, UK.

Making the announcement, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri

said, “We are delighted to welcome Dean on board Sai Life Sciences as we open our new

Process R&D facility in Manchester, UK. His joining strengthens our vision of creating a

world-class, global process R&D organization that applies cutting edge scientific approaches and

technology to rapidly deliver high-quality scientific output irrespective of the geographical location.”

As part of its organization-wide transformation initiative, Sai Nxt [https://www.sailife.com/sai-life-sciences-announces-sai-nxt-an-initiative-to-transform-the-organization-into-a-new-generation-cdmo/?utm_source=dean-edney-pr ], the company aspires to enhance

its Process Research & Development (PR&D) capability allowing customers to accelerate

their research and development programs and deliver commercial products through the rapid

application of high quality science to all areas of API process research, development and

manufacturing. It will achieve this by combining expertise in rapid, cost effective, process

optimisation and scale-up in Hyderabad with expertise in application of new technology and

parallel & statistical approaches to process development in Manchester into a single global

PR&D organisation.

Commenting on his appointment, Dean Edney said, "I am incredibly excited to be joining

Sai Life Sciences at a time of significant investment and growth. My aim is to ensure that

the investment in facilities and technology is matched by investment in people and capability,

thereby accelerating our clients’ ability to deliver new medicines to patients.” Previously,

over a 25-year career at GlaxoSmithKline, Dean demonstrated a strong track record of

cross-functional leadership to deliver projects and develop capability across all phases of

API process research & development, from early non-clinical supply and route scouting

through to validation of commercial control strategies.  Dean received his BSc in Chemistry

and Ph.D. in Synthetic Organic Chemistry from the University of Nottingham, UK.

About Sai Life Sciences

Sai Life Sciences is a full-service CDMO [https://www.sailife.com/?utm_source=dean-edney-pr ]

driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator

pharma and biotech companies globally, accelerating the discovery, development and

manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served

a diverse set of NCE development programs, consistently delivering value based on its quality

and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as

several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held

and backed by global investors, TPG Capital and HBM Healthcare Investments. www.sailife.com

Photo: https://mma.prnewswire.com/media/1092322/Dean_Edney_Sai_Life_Sciences.jpg

Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

Source: Sai Life Sciences